Cihan Ay
Cihan Ay is an expert in Hematology at Comprehensive Cancer Center Vienna (Austria). As of October 2026, ScienceLeadR ranks Cihan Ay in the top 1% of experts worldwide for Embolism and Thrombosis and Epidemiologic Studies. Cihan Ay has authored 586 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 4 of them ongoing. SLR score: 2,259 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Cardiology - Oncology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 586
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Mental health in venous thromboembolism: A scoping review of the qualitative and quantitative evidence. PMID 42945783 — thromboembolism, hemorrhage, income, outcome assessment, health care, diagnosis, records, therapeutics, venous thromboembolism, thrombosis, mental health, hemostasis | Thromb Res | 2026 | 0 |
| Early outcomes after venous thromboembolism in Hispanic and non-Hispanic patients: insights from the Registro Informatizado de Enfermedad TromboEmbólica Registry. PMID 42893102 — registries, mortality, thromboembolism, hemorrhage, pulmonary embolism, outcome assessment, health care, venous thromboembolism | Res Pract Thromb Haemost | 2026 | 0 |
| Systemic inflammation and patient-reported quality of life as combined prognosticators in patients with solid tumors. PMID 42892236 — quality of life, neoplasms | Eur J Cancer | 2026 | 0 |
| KRAS Mutation and Venous Thromboembolism Risk in Colorectal Cancer: A Danish Population-Based Cohort Study. PMID 42829084 — research design, thromboembolism, embolism, neoplasms, cohort studies, venous thromboembolism, thrombosis, colorectal neoplasms, mutation | J Thromb Haemost | 2026 | 0 |
| Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes. PMID 42787640 — cells, research design, lung, blood coagulation, venous thrombosis, neoplasms, carcinoma, non-small-cell lung, drug therapy, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma, head and neck neoplasms, therapeutics, thrombosis, globulins, plasma, chemotherapy | Res Pract Thromb Haemost | 2026 | 0 |
Clinical Studies 15
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A 2025-522435-33-00 — safety, hemophilia a, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A 2025-522434-32-00 — factor viii, safety, hemophilia a, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A 2025-520490-38-00 — work, hemophilia a, research | Phase 1 | Not yet recruiting | 2025 |
| Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease NCT07273721 — safety, hemorrhage, pharmaceutical preparations, von willebrand diseases, von willebrand factor, thrombocytopenia | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map